Your browser doesn't support javascript.
Perspective: the nose and the stomach play a critical role in the NZACE2-Patari* (modified ACE2) drug treatment project of SARS-CoV-2 infection.
Ameratunga, Rohan; Woon, See-Tarn; Steele, Richard; Snell, Russell; Medlicott, Natalie; Mears, Emily; Leung, Euphemia; Lehnert, Klaus; Jordan, Anthony; Das, Shyamal; Abbott, William; Longhurst, Hilary; Quiñones-Mateu, Miguel E.
  • Ameratunga R; Department of Clinical Immunology, Auckland Hospital, Auckland New Zealand.
  • Woon ST; Department of Virology and Immunology, Auckland Hospital, Auckland, New Zealand.
  • Steele R; Department of Molecular Medicine and Pathology, School of Medicine, Faculty of Medical and Health Sciences, University of Auckland.
  • Snell R; Department of Virology and Immunology, Auckland Hospital, Auckland, New Zealand.
  • Medlicott N; Department of Virology and Immunology, Auckland Hospital, Auckland, New Zealand.
  • Mears E; Department of Respiratory Medicine, Wellington Hospital, Wellington, New Zealand.
  • Leung E; Centre for Brain Research, School of Biological Sciences, University of Auckland, Symonds St, Auckland, New Zealand.
  • Lehnert K; School of Pharmacy, University of Otago, Dunedin, New Zealand.
  • Jordan A; Centre for Brain Research, School of Biological Sciences, University of Auckland, Symonds St, Auckland, New Zealand.
  • Das S; Auckland Cancer Society Research Centre, School of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
  • Abbott W; Centre for Brain Research, School of Biological Sciences, University of Auckland, Symonds St, Auckland, New Zealand.
  • Longhurst H; Department of Clinical Immunology, Auckland Hospital, Auckland New Zealand.
  • Quiñones-Mateu ME; School of Pharmacy, University of Otago, Dunedin, New Zealand.
Expert Rev Clin Immunol ; 17(6): 553-560, 2021 06.
Article in English | MEDLINE | ID: covidwho-1165061
ABSTRACT

Background:

COVID-19 has caused calamitous health, economic and societal consequences globally. Currently, there is no effective treatment for the infection. Areas covered We have recently described the NZACE2-Patari project, which seeks to administer modified Angiotensin Converting Enzyme 2 (ACE2) molecules early in the infection to intercept and block SARS-CoV-2 binding to the pulmonary epithelium. Expert opinion Since the nasopharyngeal mucosa is infected in the first asymptomatic phase of the infection, treatment of the nose is likely to be safe and potentially effective. The intercepted virus will be swallowed and destroyed in the stomach. There is however a limited window of opportunity to alter the trajectory of the infection in an individual patient, which requires access to rapid testing for SARS-CoV-2. The proposed strategy is analogous to passive immunization of viral infections such as measles and may be of particular benefit to immunodeficient and unvaccinated individuals.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Stomach / Nasopharynx / Respiratory Mucosa / Angiotensin-Converting Enzyme 2 / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Prognostic study Limits: Humans Language: English Journal: Expert Rev Clin Immunol Journal subject: Allergy and Immunology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Stomach / Nasopharynx / Respiratory Mucosa / Angiotensin-Converting Enzyme 2 / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Prognostic study Limits: Humans Language: English Journal: Expert Rev Clin Immunol Journal subject: Allergy and Immunology Year: 2021 Document Type: Article